Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Institute for Neurodegenerative Disorders)"
Count: 49
Selected: 0
NCT IDTitle
NCT00132626Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
NCT01767493Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
NCT01462708Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
NCT01461109Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
NCT01461083Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
NCT01268020Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
NCT01217021Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01209156Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01028209Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01000870Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
NCT00970333Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
NCT00970229Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
NCT00968097Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
NCT00886951Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
NCT00870974A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
NCT00870519Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00657813Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
NCT00612872Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
NCT00605059Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00605046Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
NCT00556764Development of Cognitive Assessment Tools in Parkinson Disease
NCT00556660Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00480701Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
NCT00470925Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects
NCT00456417Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
NCT00427674Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
NCT00404170Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
NCT00397696Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
NCT00387075A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
NCT00354003The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
NCT00316797Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
NCT00315250Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
NCT00287248Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
NCT00273351Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
NCT00134784Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
NCT00129675Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
NCT00129181Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease
NCT00117819A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
NCT00117195A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
NCT00096876A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
NCT00096720Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
NCT04906590PPMI Tau PET Imaging
NCT04477785PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort
NCT02103894Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
NCT01141023Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
NCT00448799Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
NCT00439010Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
NCT00397228ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
NCT02370524Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease